Ultra-concentrated rapid-acting insulin analogue formulations
A pharmaceutical formulation comprises insulin having a variant insulin B-chain polypeptide containing an ortho-monofluoro-Phenylalanine substitution at position B24 in combination with a substitution of an amino acid containing an acidic side chain at position B10, allowing the insulin to be present at a concentration of between 0.6 mM and 3.0 mM. The formulation may optionally be devoid of zinc. Amino-acid substitutions at one or more of positions B3, B28, and B29 may additionally be present. The variant B-chain polypeptide may be a portion of a proinsulin analog or single-chain insulin analog. The insulin analog may be an analog of a mammalian insulin, such as human insulin. A method of lowering the blood sugar of a patient comprises administering a physiologically effective amount of the insulin analog or a physiologically acceptable salt thereof to the patient.
1. A pharmaceutical formulation comprising insulin, wherein the insulin B-chain polypeptide comprises an ortho-monofluoro-Phenylalanine substitution at position B24 in relation to the sequence of human insulin, in combination with a substitution of Aspartic Acid at position B10 in relation to the sequence of human insulin, a substitution of Glutamic Acid at position B29 in relation to the sequence of human insulin, and a substitution of Glutamic Acid at position A8 in relation to the sequence of human insulin, wherein the insulin is present at a concentration of between 0.6 mM and 3.0 mM.
2. The pharmaceutical formulation of claim 1 , wherein the insulin is present at a concentration of at least 2 mM.
3. The pharmaceutical formulation of claim 1 , wherein the B chain polypeptide additionally contains a substitution at position B28 in relation to the sequence of human insulin selected from the group consisting of Aspartic Acid and Lysine.
4. The pharmaceutical formulation of claim 1 , wherein the B-chain polypeptide also contains a Lysine substitution at position B3 in relation to the sequence of human insulin.
5. The pharmaceutical formulation of claim 4 , wherein the B chain polypeptide comprises SEQ ID NO: 8, wherein the Xaa at residue 10 is Asp.
6. The pharmaceutical formulation of claim 1 , wherein an A-chain polypeptide sequence has the amino acid sequence of SEQ ID NO: 9, wherein the Xaa at residue 8 is Glu.
7. A polypeptide comprising the insulin B-chain polypeptide sequence containing an ortho-monofluoro-Phenylalanine substitution at position B24 in relation to the sequence of human insulin, in combination with: a substitution of Aspartic Acid at position B10 in relation to the sequence of human insulin, a substitution of Glutamic Acid at position B29 in relation to the sequence of human insulin, and a substitution of Glutamic Acid at position A8 in relation to the sequence of human insulin.
8. The polypeptide of claim 7 , wherein the polypeptide is a proinsulin analogue or single-chain insulin analogue.
9. The polypeptide of claim 7 , wherein the polypeptide additionally contains a Lysine substitution at position B3 in relation to the sequence of human insulin.
10. A method of lowering the blood sugar level of a patient, the method comprising administering the pharmaceutical formulation of claim 1 to said patient.
11. The method of claim 10 , wherein the insulin is present in the formulation at a concentration of at least 2 mM.